Feline CCL5/RANTES Biotinylated Antibody

R&D Systems, part of Bio-Techne | Catalog # BAF3819

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
BAF3819
Print Quote
Bulk Order
Conjugate
Catalog #
Unconjugated
AF3819
View Product
100% Guarantee

Key Product Details

Species Reactivity

Feline

Applications

ELISA Detection (Matched Antibody Pair), Western Blot

Label

Biotin

Antibody Source

Polyclonal Sheep IgG

View all CCL5/RANTES Antibodies »

Product Specifications

Immunogen

E. coli-derived recombinant feline CCL5/RANTES

Specificity

Detects feline RANTES in ELISAs and Western blots. In sandwich immunoassays, less than 0.02% cross-reactivity with recombinant human RANTES, recombinant mouse RANTES, and recombinant cotton rat RANTES is observed.

Clonality

Polyclonal

Host

Sheep

Isotype

IgG

Applications for Feline CCL5/RANTES Biotinylated Antibody

Application
Recommended Usage

Western Blot

0.1 µg/mL
Sample: Recombinant Feline CCL5/RANTES (Catalog # 3819-FR)

Feline CCL5/RANTES Sandwich Immunoassay

ELISA Detection (Matched Antibody Pair)
Recommended Concentration: 0.1-0.4 µg/mL
Use in combination with these reagents:
  • Capture Reagent: Feline CCL5/RANTES Antibody (Catalog # AF3819)
  • Standard: Recombinant Feline CCL5/RANTES Protein (Catalog # 3819-FR)
Please Note: Optimal dilutions of this antibody should be experimentally determined.

Formulation, Preparation, and Storage

Purification

Antigen Affinity-purified

Reconstitution

Reconstitute at 0.2 mg/mL in sterile PBS.

Reconstitution Buffer Available:
Size / Price
Qty

Formulation

Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: CCL5/RANTES

CCL5, also known as RANTES (Regulated upon Activation, Normal T cell Expressed and presumably Secreted), is an 8 kDa beta-chemokine that plays a primary role in the inflammatory immune response by means of its ability to attract and activate leukocytes (1‑3). Human and mouse RANTES exhibit cross-species activity on human and mouse cells (4). Mature feline CCL5 shares 84% aa seqeuence identity with canine CCL5 and 71%‑75% with cotton rat, human, mouse, and rat CCL5 (5). CCL5 is secreted by many cell types at inflammatory sites, and it exerts a wide range of activities through the receptors CCR1, CCR3, CCR4, and CCR5 (6, 7). Inflammatory responses can be impaired by the sequestration of CCL5 by the cytomegalovirus protein US28 (8). In humans, CCR5 binding to CCL5 inhibits the infectivity of R5 (M-tropic) but not X4 (T-tropic) strains of HIV-1 (9). The two N-terminal residues of CCL5 can be removed by CD26/DPPIV, generating a protein that functions as a chemotaxis inhibitor and more effectively blocks M-tropic HIV-1 infection of monocytes (10). Oligomerization of CCL5 on glycosaminoglycans is required for CCR1-mediated leukocyte adhesion and activation as well as CCL5’s interaction with the chemokine CXCL4/PF4 (11‑13). The deposition of CCL5 on activated vascular endothelial cells is crucial for monocyte adhesion to damaged vasculature, but CCL5 oligomerization is not required for the extravasation of adherent leukocytes (14‑16). CCL5 is upregulated in breast cancer and promotes tumor progression through the attraction of proinflammatory macrophages in addition to its actions on tumor cells, stromal cells, and the vasculature (17).

References

  1. Schall, T.J. et al. (1990) Nature 347:669.
  2. Bacon, K.B. et al. (1995) Science 269:1727.
  3. Fischer, F.R. et al. (2001) J. Immunol. 167:1637.
  4. Schall, T.J. et al. (1992) Eur. J. Immunol. 22:1477.
  5. Kimura, T. et al. (2003) Vet. Dermatol. 14:269.
  6. Appay, V. and S.L. Rowland-Jones (2001) Trends Immunol. 22:83.
  7. Levy, J.A. (2009) J. Immunol. 182:3945.
  8. Randolph-Habecker, J.R. et al. (2002) Cytokine 19:37.
  9. DeVico, A.L. and Gallo, R.C. (2004) Nat. Rev. Microbiol. 2:401.
  10. Proost, P. et al. (1998) J. Biol. Chem. 273:7222.
  11. Appay, V. et al. (1999) J. Biol. Chem. 274:27505.
  12. Proudfoot, A.E.I. et al. (2003) Proc. Natl. Acad. Sci. 100:1885.
  13. von Hundelshausen, P. et al. (2005) Blood 105:924.
  14. von Hundelshausen, P. et al. (2001) Circulation 103:1772.
  15. Zernecke, A. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1897.
  16. Baltus, T. et al. (2003) Blood 102:1985.
  17. Soria, G. and A. Ben-Baruch (2008) Cancer Lett. 267:271.

Alternate Names

RANTES, SISd

Entrez Gene IDs

6352 (Human); 20304 (Mouse); 403522 (Canine); 493689 (Feline)

Gene Symbol

CCL5

Additional CCL5/RANTES Products

Product Documents for Feline CCL5/RANTES Biotinylated Antibody

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Feline CCL5/RANTES Biotinylated Antibody

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.